AC Immune
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 161
- Market Cap
- $302.7M
- Website
- http://www.acimmune.com
- Introduction
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease
- Conditions
- Parkinson DiseaseParkinson Disease 6, Early-Onset
- Interventions
- Biological: ACI-7104.056 at Dose ABiological: ACI-7104.056 at Dose B (optional)Biological: ACI-7104.056 at Dose C (optional)Biological: Placebo
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- AC Immune SA
- Target Recruit Count
- 150
- Registration Number
- NCT06015841
- Locations
- 🇩🇪
Katholisches Klinikum Bochum GmbH, Bochum, Germany
🇬🇧Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom
🇪🇸Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
- Conditions
- Amyloid PlaqueAlzheimer's Disease in Down SyndromeAlzheimer's DiseaseProdromal Alzheimer's DiseaseBeta-Amyloid
- Interventions
- Biological: PlaceboBiological: ACI-24.060 at Dose YBiological: ACI-24.060 at Dose ABiological: ACI-24.060 at Dose BBiological: ACI-24.060 at Dose DBiological: ACI-24.060 at Dose XBiological: ACI-24.060 at Dose C
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- AC Immune SA
- Target Recruit Count
- 140
- Registration Number
- NCT05462106
- Locations
- 🇺🇸
Indiana University / IU Health, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UT Health San Antonio, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
- Conditions
- Cognitive ImpairmentMild Cognitive ImpairmentDementiaBrain DiseasesAlzheimer's DiseaseTauopathiesCentral Nervous System Diseases
- Interventions
- Biological: ACI-35.030Other: PlaceboBiological: JACI-35.054
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AC Immune SA
- Target Recruit Count
- 57
- Registration Number
- NCT04445831
- Locations
- 🇫🇮
Clinical Research Services Helsinki, Helsinki, Finland
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇸🇪Minnesmottagningen - Sahlgrenska Universitetssjukhuset - Mölndal Sjukhus, Mölndal, Sweden
A Study of ACI-24 in Adults With Down Syndrome
- Conditions
- Down Syndrome
- Interventions
- Biological: ACI-24Biological: Placebo
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- AC Immune SA
- Registration Number
- NCT04373616
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
- Conditions
- Down Syndrome
- Interventions
- Biological: ACI-24 low doseBiological: PlaceboBiological: ACI-24 high dose
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- AC Immune SA
- Target Recruit Count
- 20
- Registration Number
- NCT02738450
- Locations
- 🇺🇸
UCSD Adult Down Syndrome Program, La Jolla, California, United States
🇺🇸St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States